Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for chronic kidney disease
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronickidneydisease&mdash KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronickidneydisease—mineral and bone disorder (CKD-MBD). | National Guideline Clearinghouse success fail JUN 09 2017 2018 2019 14 Apr 2018 - 12 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused (...) , read our . Guideline Summary NGC:011233 2017 Jul NEATS Assessment KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronickidneydisease—mineral and bone disorder (CKD-MBD). KidneyDisease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronickidneydisease–mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017 Jul;7
ChronickidneydiseaseChronickidneydisease - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search Chronickidneydisease Last reviewed: February 2019 Last updated: September 2018 Summary Proteinuria or haematuria, and/or a reduction in the glomerular filtration rate, for more than 3 months' duration. The most common causes are diabetes mellitus and hypertension. The majority of people are asymptomatic, and the diagnosis (...) is determined only by laboratory studies. Glycaemic control for diabetic nephropathy and optimisation of blood pressure are key in slowing the progression of disease. Increased risk for cardiovascular disease. Definition Chronickidneydisease (CKD), also known as chronic renal failure, is defined by either a pathological abnormality of the kidney, such as haematuria and/or proteinuria, or a reduction in the glomerular filtration rate to <60 mL/minute/1.73 m² for ≥3 months' duration. KidneyDisease
KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of ChronicKidneyDisease-Mineral and Bone Disorder (CKD-MBD) KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of ChronicKidneyDisease–Mineral and Bone Disorder (CKD-MBD) - American Journal of KidneyDiseases Email/Username: Password: Remember me Search Terms Search within Search Share (...) this page Access provided by Volume 70, Issue 6, Pages 737–751 KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of ChronicKidneyDisease–Mineral and Bone Disorder (CKD-MBD) x Tamara Isakova Affiliations Division of Nephrology and Hypertension, Department of Medicine and Center for Translational Metabolism and Health, Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL
Urinary Calcium Excretion and Risk ofÂ ChronicKidneyDisease in the GeneralÂ Population High urinary calcium excretion (UCaE) has been shown to lead to accelerated renal function decline in individuals with renal tubular diseases. It is not known whether this association also exists in the general population. Therefore, we investigated whether high UCaE is associated with risk of developing chronickidneydisease (CKD) in community-dwelling subjects.Urine samples of 5491 subjects who were free (...) of CKD at baseline and participated in the Prevention of Renal and Vascular End-Stage Disease study (a prospective, observational, general population-based cohort of Dutch men and women aged 28-75 years) were examined for UCaE. UCa concentration was measured in two 24-hour urine samples at baseline (1997-1998) by indirect potentiometry. UCaE was treated as a continuous variable and a categorical variable grouped according to sex-specific quintiles for UCaE. UCaE was compared with de novo development
Oral Magnesium Supplementation in ChronicKidneyDisease Stages 3 and 4: Efficacy, Safety, and Effect on Serum Calcification Propensityâ€”AÂ Prospective Randomized Double-Blinded Placebo-Controlled Clinical Trial Chronickidneydisease (CKD) is associated with high cardiovascular morbidity and mortality. Recent evidence suggests that increases in both serum and intracellular magnesium (Mg) can slow or even prevent the development of vascular calcification seen in CKD. Serum calcification
Traditional Thermal Therapy with Indirect Moxibustion Decreases Renal Arterial Resistive Index in Patients with ChronicKidneyDisease. To evaluate the immediate effects of traditional local thermal therapy with indirect moxibustion on renal hemodynamics in patients with chronickidneydisease (CKD) by using Doppler ultrasonography (US).Examiner-blinded crossover study.Forty-three participants with CKD (mean age ± standard deviation [SD], 44 ± 15 years; estimated glomerular filtration rate
ChronicKidneyDisease. The definition and classification of chronickidneydisease (CKD) have evolved over time, but current international guidelines define this condition as decreased kidney function shown by glomerular filtration rate (GFR) of less than 60 mL/min per 1·73 m2, or markers of kidney damage, or both, of at least 3 months duration, regardless of the underlying cause. Diabetes and hypertension are the main causes of CKD in all high-income and middle-income countries, and also (...) is measured either via exogenous markers (eg, DTPA, iohexol), or estimated using equations. Presence of proteinuria is associated with increased risk of progression of CKD and death. Kidney biopsy samples can show definitive evidence of CKD, through common changes such as glomerular sclerosis, tubular atrophy, and interstitial fibrosis. Complications include anaemia due to reduced production of erythropoietin by the kidney; reduced red blood cell survival and iron deficiency; and mineral bone disease
Metabolically Healthy Obesity and Development of ChronicKidneyDisease 27842407 2017 12 07 2018 12 02 1539-3704 165 10 2016 11 15 Annals of internal medicine Ann. Intern. Med. Metabolically Healthy Obesity and Development of ChronicKidneyDisease. 743 10.7326/L16-0407 Kahn Henry S HS From Centers for Disease Control and Prevention, Atlanta, Georgia. Pavkov Meda E ME From Centers for Disease Control and Prevention, Atlanta, Georgia. eng CC999999 Intramural CDC HHS United States Journal Article (...) Comment United States Ann Intern Med 0372351 0003-4819 AIM IM Ann Intern Med. 2016 Mar 1;164(5):305-12 26857595 Ann Intern Med. 2016 Nov 15;165(10 ):744-745 27842405 Body Mass Index Humans Obesity Obesity, Metabolically Benign Renal Insufficiency, Chronic 2016 11 15 6 0 2016 11 15 6 0 2017 12 8 6 0 ppublish 27842407 2582915 10.7326/L16-0407 PMC5308792 NIHMS848359 Int J Obes (Lond). 2016 May;40(5):883-6 26841729 PLoS One. 2016 Jan 05;11(1):e0146057 26731527 Ann Intern Med. 2016 Mar 1;164(5):305-12
Interventions for chronickidneydisease-associated restless legs syndrome. Restless legs syndrome (RLS) is defined as the spontaneous movement of the limbs (mainly legs) associated with unpleasant, sometimes painful sensation which is relieved by moving the affected limb. Prevalence of RLS among people on dialysis has been estimated between 6.6% and 80%. RLS symptoms contribute to impaired quality of life and people with RLS are shown to have increased cardiovascular morbidity (...) and mortality.Various pharmacological and non-pharmacological interventions have been used to treat primary RLS. However, the evidence for use of these interventions in people with chronickidneydisease (CKD) is not well established. The agents used in the treatment of primary RLS may be limited by the side effects in people with CKD due to increased comorbidity and altered drug pharmacokinetics.The aim of this review was to critically look at the benefits, efficacy and safety of various treatment options used
Sarcopenia, Obesity, and Mortality in US Adults With and Without ChronicKidneyDisease In pre-dialysis chronickidneydisease (CKD), the association of muscle mass with mortality is poorly defined, and no study has examined outcomes related to the co-occurrence of low muscle mass and excess adiposity (sarcopenic-obesity). Methods: We examined abnormalities of muscle and fat mass in adult participants of the National Health and Nutrition Examination Survey 1999-2004. We determined whether
Downregulation of AdipoR1 is Associated with increased Circulating Adiponectin Levels in Serbian ChronicKidneyDisease Patients Since the rise in plasma adiponectin levels in chronickidneydisease (CKD) patients has not yet been elucidated, we sought to investigate if patients on hemodialysis (HD) have altered expression of adiponectin receptors in peripheral blood mononuclear cells (PBMCs) compared to healthy subjects.This study included 31 patients with chronickidneydisease on HD and 33
Hypertension Control, Apparent Treatment Resistance, and Outcomes in the Elderly Population With ChronicKidneyDiseaseChronickidneydisease (CKD) is often associated with poor hypertension control and treatment resistance, but whether CKD modifies the effect of hypertension control on outcomes is unknown.We studied 10-year mortality and cardiovascular events according to hypertension control status and CKD (glomerular filtration rate <60 ml/min/1.73m2) in 4262 community-dwelling individuals
Tackling the Fallout From ChronicKidneyDisease of Unknown Etiology: Why We Need to Focus on Providing Peritoneal Dialysis in Rural, Low-Resource Settings 29142936 2018 11 13 2468-0249 2 1 2017 Jan Kidney international reports Kidney Int Rep Tackling the Fallout From ChronicKidneyDisease of Unknown Etiology: Why We Need to Focus on Providing Peritoneal Dialysis in Rural, Low-Resource Settings. 1-4 10.1016/j.ekir.2016.10.004 Nanayakkara Nishanthe N Department of Medicine, Teaching Hospital (...) A Department of Medicine, Division of Nephrology, Stanford University School of Medicine, Palo Alto, California, USA. Department of Medicine, Division of Nephrology, Santa Clara Valley Medical Center, San Jose, California, USA. Anand Shuchi S Department of Medicine, Division of Nephrology, Stanford University School of Medicine, Palo Alto, California, USA. eng K23 DK101826 DK NIDDK NIH HHS United States Editorial 2016 10 26 United States Kidney Int Rep 101684752 2468-0249 2017 11 17 6 0 2017 11 17 6 0 2017
Timely Referral to Outpatient Nephrology Care Slows Progression and Reduces Treatment Costs of ChronicKidneyDiseases We present a new approach to evaluate the importance of ambulatory nephrology care in patients with chronickidneydisease (CKD).An anonymized health claims database of German insurance companies was searched in a retrospective analysis for patients with CKD using the codes of the International Classification of Diseases, 10th German modification. A total of 105,219 patients (...) with CKD were identified. Patients were assigned to the group "timely referral," when nephrology care was present in the starting year 2009, or initiated during the following 3 years in CKD1-4. Using frequency matching for age and gender, 21,024 of the late referral group were matched with the equal number of patients in the timely referral group. Hospital admission rates, total treatment costs, and kidney function (change in CKD stages, start of dialysis, mortality) were documented each year during
Interventions for chronickidneydisease in people with sickle cell disease. This is the protocol for a review and there is no abstract. The objectives are as follows: To assess the effectiveness of any intervention in preventing or reducing kidney complications or CKD in people with SCD (including red blood cell transfusions, hydroxyurea and ACEI (either alone or in combination with each other)).
The Green Tea Polyphenol(â€”)-epigallocatechin-3-gallate and its beneficial roles in chronickidneydiseaseChronickidneydisease (CKD), a condition that affects around 10% of the population, has become a significant public health concern. Current therapeutic strategies to slow down the progression of CKD remain limited. Thus, it is urgent to develop new strategies to manage the patients with CKD. Work within the past decade has improved our understanding of the mechanisms contributing to CKD (...) . In particular, oxidative stress as well as inflammation appears to play a pivotal role in CKD progression. ()-Epigallocatechin-3-gallate (EGCG), the major catechin of green tea extract, is known as a powerful antioxidant and reactive oxygen species scavenger. Various studies have shown EGCG has a potential role in chronickidneydisease models. It is suggested that EGCG modulates cellular and molecular mechanisms via inflammation-related NF-кB and Nrf2 signaling pathway, as well as apoptosis-related ER
Sevelamer for the Treatment of Patients with ChronicKidneyDisease: A Review of Clinical and Cost-Effectiveness Sevelamer for the Treatment of Patients with ChronicKidneyDisease: A Review of Clinical and Cost-Effectiveness | CADTH.ca Find the information you need Sevelamer for the Treatment of Patients with ChronicKidneyDisease: A Review of Clinical and Cost-Effectiveness Sevelamer for the Treatment of Patients with ChronicKidneyDisease: A Review of Clinical and Cost-Effectiveness (...) Published on: September 21, 2016 Project Number: RC0810-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of sevelamer for the treatment of patients with chronickidneydisease? What is the cost-effectiveness of sevelamer for the treatment of patients with chronickidneydisease? Key Message Overall, the evidence suggests that sevelamer is more effective at reducing serum calcium levels and lowering
Depression in ChronicKidneyDisease and End-Stage Renal Disease: Similarities and Differences in Diagnosis, Epidemiology, andÂ Management Depression is highly prevalent and is associated with poor quality of life and increased mortality among adults with chronickidneydisease (CKD), including those with end-stage renal disease (ESRD). However, there are several important differences in the diagnosis, epidemiology, and management of depression between patients with non-dialysis-dependent CKD
Evaluation of Renal Blood Flow in ChronicKidneyDisease Using Arterial Spin Labeling Perfusion Magnetic Resonance Imaging Chronickidneydisease (CKD) is known to be associated with reduced renal blood flow. However, data to-date in humans is limited.In this study, non-invasive arterial spin labeling (ASL) MRI data was acquired in 33 patients with diabetes and stage-3 CKD, and 30 healthy controls.A significantly lower renal blood flow both in cortex (108.4±36.4 vs. 207.3±41.8; p<0.001, d=2.52
Iron (III) isomaltoside 1000 (Diafer) - iron deficiency in adults with chronickidneydisease (CKD) on dialysis 1 Published 13 February 2017 Re-submission iron III isomaltoside 1000 (contains 50mg iron per mL) (Diafer ® ), solution for injection SMC No. (1177/16) Pharmacosmos UK Limited 13 January 2017 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in Scotland (...) . The advice is summarised as follows: ADVICE: following a resubmission iron III isomaltoside 1000 5% (Diafer ® ) is accepted for use within NHS Scotland. Indication under review: For the treatment of iron deficiency in adults with chronickidneydisease (CKD) on dialysis, when oral iron preparations are ineffective or cannot be used. Iron III isomaltoside 1000 at a higher (10%) concentration has been shown to be non-inferior to another intravenous iron product in maintaining haemoglobin concentration